---
title: "Enhertu (fam-trastuzumab deruxtecan-nxki), all indications: Dosing and administration questions"
description: "Dosing and administration questions on Enhertu (fam-trastuzumab deruxtecan-nxki) that apply to every indication, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Premedication, Dosing, Administration, Before treatment, and Preparation. Questions: Does Enhertu need anti-nausea premedication? What are the Enhertu dose reduction levels? What if an Enhertu dose is missed or delayed? How long does an Enhertu infusion take? 3 further questions follow. 7 questions quoted from 4 sources."
canonical: "https://www.evicenter.com/medical-information/enhertu/dosing-and-administration"
published: "2026-11-14T01:54:55-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Enhertu (fam-trastuzumab deruxtecan-nxki), all indications: Dosing and administration questions

Manufacturer: Daiichi Sankyo, Inc.; AstraZeneca Pharmaceuticals LP  
Prescribing information: [Enhertu](https://daiichisankyo.us/prescribing-information-portlet/getPIContent?productName=Enhertu&inline=true)  
Indication pages: [HR-positive HER2-low or HER2-ultralow breast cancer](https://www.evicenter.com/medical-information/enhertu--hr-positive-her2-low-or-her2-ultralow-breast-cancer)

## Premedication

<a id="enhertu-nausea-premedication"></a>

### Does Enhertu need anti-nausea premedication?

> “INITIATE PROPHYLAXIS: ENHERTU is highly emetogenic, which can cause delayed nausea and/or vomiting. Administer prophylactic antiemetic medications per local institutional guidelines for prevention of chemotherapy-induced nausea and vomiting<sup>1</sup>”

Source: [ENHERTU: Dosage, captured 2026-11-13](https://www.enhertuhcp.com/en/dosing/dosage#:~:text=INITIATE%20PROPHYLAXIS%3A%20ENHERTU%20is%20highly,prevention%20of%20chemotherapy%2Dinduced%20nausea%20and)

> “Fam-trastuzumab deruxtecan-nxki (ENHERTU<sup>®</sup>) is classified as highly emetogenic, which includes delayed nausea and/or vomiting<sup>1,2</sup>”

Source: [ENHERTU: Select Adverse Reactions, captured 2026-11-13](https://www.enhertuhcp.com/en/managing-adverse-reactions/other-select-adverse-reactions#:~:text=Fam%2Dtrastuzumab%20deruxtecan%2Dnxki,which%20includes%20delayed%20nausea%20and%2For)

## Dosing

<a id="enhertu-dose-reductions"></a>

### What are the Enhertu dose reduction levels?

> “Dose reduction schedule
>
> Breast Cancer,
> NSCLC, and IHC 3+
> Solid Tumors
>
> Gastric Cancer
>
> Recommended starting dose	5.4 mg/kg	6.4 mg/kg
> First dose reduction	4.4 mg/kg	5.4 mg/kg
> Second dose reduction	3.2 mg/kg	4.4 mg/kg
> Requirement for further dose reduction	Discontinue treatment”

Source: [ENHERTU: Dosage, captured 2026-11-13](https://www.enhertuhcp.com/en/dosing/dosage#:~:text=Dose%20reduction%20schedule,Discontinue%20treatment)

> “Do not re-escalate the ENHERTU dose after a dose reduction is made”

Source: [ENHERTU: Dosage, captured 2026-11-13](https://www.enhertuhcp.com/en/dosing/dosage#:~:text=Do%20not%20re%2Descalate%20the%20ENHERTU%20dose%20after%20a%20dose%20reduction%20is%20made)

Note: The first column (5.4 mg/kg starting dose) applies to breast cancer, including HER2-low and HER2-ultralow metastatic breast cancer; the second column applies to gastric cancer.

<a id="enhertu-missed-dose"></a>

### What if an Enhertu dose is missed or delayed?

> “If a planned dose is delayed or missed, administer as soon as possible; do not wait until the next planned cycle. Adjust the schedule of administration to maintain a 3-week interval between doses. Administer the infusion at the dose and rate the patient tolerated in the most recent infusion”

Source: [ENHERTU: Dosage, captured 2026-11-13](https://www.enhertuhcp.com/en/dosing/dosage#:~:text=If%20a%20planned%20dose%20is,in%20the%20most%20recent%20infusion)

## Administration

<a id="enhertu-infusion-time"></a>

### How long does an Enhertu infusion take?

> “First infusion: Administer infusion over 90 minutes
> Subsequent infusions: Administer over 30 minutes if prior infusions were well tolerated”

Source: [ENHERTU: Preparation and Administration, captured 2026-11-13](https://www.enhertuhcp.com/en/dosing/preparation-and-administration#:~:text=First%20infusion%3A%20Administer%20infusion%20over,prior%20infusions%20were%20well%20tolerated)

> “Do NOT administer as an intravenous push or bolus”

Source: [ENHERTU: Preparation and Administration, captured 2026-11-13](https://www.enhertuhcp.com/en/dosing/preparation-and-administration#:~:text=Do%20NOT%20administer%20as%20an%20intravenous%20push%20or%20bolus)

> “Administer ENHERTU with a 0.20 or 0.22 micron in-line polyethersulfone (PES) or polysulfone (PS) filter”

Source: [ENHERTU: Preparation and Administration, captured 2026-11-13](https://www.enhertuhcp.com/en/dosing/preparation-and-administration#:~:text=Administer%20ENHERTU%20with%20a%200.20,%28PES%29%20or%20polysulfone%20%28PS%29%20filter)

## Before treatment

<a id="enhertu-before-each-dose"></a>

### What should be checked before starting Enhertu and during treatment?

> “Before administering ENHERTU
> • Monitor complete blood counts prior to initiation and prior to each dose,  
> and as clinically indicated
> • Assess LVEF prior to initiation and at regular intervals during treatment as  
> clinically indicated
> • Verify pregnancy status of females”

Source: [ENHERTU: Infusion Guide, page 4, captured 2026-11-13](https://www.enhertuhcp.com/-/media/pantumor_hcp/files/dosing-and-administration-guide.pdf?rev=4638239dab7b4732976ab0af58aebd07&hash=F25AAB4C6F49DE3080CDCF6F999C9245#page=4)

## Preparation

<a id="enhertu-preparation"></a>

### How is Enhertu reconstituted and diluted?

> “Reconstitution<sup>1</sup>
> Reconstitute immediately before dilution
> More than one vial may be needed for a full dose. Calculate the dose (mg), the total volume of reconstituted ENHERTU solution required, and the number of vial(s) of ENHERTU needed
> Reconstitute each 100 mg vial by using a sterile syringe to slowly inject 5 mL of Sterile Water for Injection, USP into each vial to obtain a final concentration of 20 mg/mL
> Swirl the vial gently until completely dissolved. Do not shake”

Source: [ENHERTU: Preparation and Administration, captured 2026-11-13](https://www.enhertuhcp.com/en/dosing/preparation-and-administration#:~:text=Reconstitute%20immediately%20before%20dilution,completely%20dissolved.%20Do%20not%20shake)

> “Dilution<sup>1</sup>
> Withdraw the calculated amount from the vial(s) using a sterile syringe. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit. The solution should be clear and colorless to light yellow. Do not use if visible particles are observed or if the solution is cloudy or discolored
> Dilute the calculated volume of reconstituted ENHERTU in an intravenous infusion bag containing 100 mL of 5% Dextrose Injection, USP. DO NOT use Sodium Chloride Injection, USP. ENHERTU is compatible with an infusion bag made of polyvinylchloride or polyolefin (copolymer of ethylene and polypropylene)
> Gently invert the infusion bag to thoroughly mix the solution. Do not shake
> Cover the infusion bag to protect from light
> Discard any unused portion left in the vials”

Source: [ENHERTU: Preparation and Administration, captured 2026-11-13](https://www.enhertuhcp.com/en/dosing/preparation-and-administration#:~:text=Withdraw%20the%20calculated%20amount%20from,portion%20left%20in%20the%20vials)

<a id="enhertu-not-substitutable"></a>

### Can Enhertu be substituted for trastuzumab or ado-trastuzumab emtansine?

> “Do not substitute ENHERTU for or with trastuzumab or ado-trastuzumab emtansine”

Source: [ENHERTU: Dosage, captured 2026-11-13](https://www.enhertuhcp.com/en/dosing/dosage#:~:text=Do%20not%20substitute%20ENHERTU%20for%20or%20with%20trastuzumab%20or%20ado%2Dtrastuzumab%20emtansine)

> “In order to prevent medication errors, check the vial labels to ensure that the drug being prepared and administered is ENHERTU and not trastuzumab or ado-trastuzumab emtansine.<sup>1</sup>”

Source: [ENHERTU: Preparation and Administration, captured 2026-11-13](https://www.enhertuhcp.com/en/dosing/preparation-and-administration#:~:text=In%20order%20to%20prevent%20medication,and%20not%20trastuzumab%20or%20ado%2Dtrastuzumab)

## Related pages
- [Medical information: Enhertu (fam-trastuzumab deruxtecan-nxki): All indications](https://www.evicenter.com/medical-information/enhertu)
- [Indication](https://www.evicenter.com/medical-information/enhertu/indication)
- [Pharmacology](https://www.evicenter.com/medical-information/enhertu/pharmacology)
- [Safety](https://www.evicenter.com/medical-information/enhertu/safety)
- [Specific populations](https://www.evicenter.com/medical-information/enhertu/specific-populations)
- [Drug interactions](https://www.evicenter.com/medical-information/enhertu/drug-interactions)
- [Storage and supply](https://www.evicenter.com/medical-information/enhertu/storage-and-supply)
- [Access and coverage](https://www.evicenter.com/medical-information/enhertu/access-and-coverage)
- [Guidelines](https://www.evicenter.com/medical-information/enhertu/guidelines)
